CD19 CAR mRNA (Human)
Based on 1 publication(s) in Google Scholar
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
-80°C
Publications Citing Use of MedChemExpress (MCE) CD19 CAR mRNA (Human)
More
Activité biologique
Description
In Vitro
Guide (The following is our recommend protocol. This protocol is only a guide and should be modified
according to your specific needs).
1. Primary T-cell culturing
1.1 Separate primary human T cells from fresh venous primary blood using LympPrep gradient centrifugation.
1.2 Purify to 95% purity.
1.3 Keep in liquid nitrogen prior to use.
1.4 Thaw and culture cells in complete culture medium for 24 h.
1.5 Activate with Human T-Activator CD3/CD28 Dynabeads (1:1 cell to bead ratio), and incubate for 48 h.
1.6 Remove Human T-Activator beads by gently pipetting up and down then transfer to a magnetic tube rack for 1-2 min, transfer supernatant containing cells to a fresh tube.
1.7 Electroporate the cells within 24 h of bead removal.
2. mRNA transfection
2.1 Add 50 ng/μL for each system unless specified otherwise (50 ng per reaction for triDrop, 500 ng per reaction for Neon, and 1000 ng per reaction for Lonza).
2.2 tore CD19 CAR mRNA at -80 °C in aliquots
3. Electroporation
3.1 Electroporate with triDrop Electroporation, Neon Electroporation or Lonza Electroporation protocol.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[CD19 CAR mRNA (Human)]
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies. [Abstract]2025 Jun 3;97(21):11026-11034. PMID: 40390294
Protocole
-
Gene Editing
Gene editing modify specific sites within the genome through gene deletions, insertions or conversions to study functionally unknown genes or conduct gene therapy. It is also used to change the biological traits of organisms to establish new varieties. Gene editing techniques include zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas 9) (CRISPR/Cas9).
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Pureté et documentation
-
Fiche technique (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Wang, K., et al., (2012). CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental hematology & oncology, 1(1), 36. [Content Brief]
[3]. Wu, J., et al., (2024). Chimeric antigen receptor therapy meets mRNA technology. Trends in biotechnology, 42(2), 228–240. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)